These findings highlight the clinical significance of CYP19A1 in CRC and its potential role in modulating chemotherapy response, consistent with our in vitro findings demonstrating that CYP19A1 reverses chemoresistance in CRC cells. The gene discussed is CYP19A1; the disease is colorectal carcinoma.